4D Molecular Therapeutics, Inc.
FDMT
$4.11
-$0.17-3.97%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -53.86% | -327.49% | -18.02% | -12.97% | -17.91% |
| Total Depreciation and Amortization | 17.91% | 21.99% | 13.73% | 12.89% | 9.01% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 5.24% | -6.64% | -20.78% | 35.90% | 31.95% |
| Change in Net Operating Assets | -659.94% | 173.18% | -150.63% | 21.62% | 285.47% |
| Cash from Operations | -86.06% | -2,409.91% | -37.06% | -4.24% | -10.97% |
| Capital Expenditure | -72.86% | -339.01% | 56.65% | 29.84% | 49.77% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 230.57% | -4.30% | -246.11% | -694.78% | 82.32% |
| Cash from Investing | 205.64% | -8.94% | -249.20% | -710.38% | 81.32% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -87.38% | -94.33% | -86.83% | 2,781.97% | 89.42% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -87.38% | -94.62% | -86.78% | 2,800.05% | 132.75% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -43.78% | -103.87% | -154.86% | 1.02% | 52.51% |
